LobbyingBeone Medicines USA lobbying by quarter
Beone Medicines USA's latest lobbying report covers Q2 2026, at $350K. The four quarters Q3 2025–Q2 2026 total $1.1M. Its first report covers Q4 2022; the issues it reports most are Health Issues and Accounting.
Beone Medicines USA
- Latest quarter
- $350K
- Q2 2026 · 1 reports
- Last 12 months
- $1.1M
- Last 4 quarters
- vs last quarter
- +40.0%
- Q2 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $120K | 1 |
| Q1 2023 | $250K | 1 |
| Q2 2023 | $140K | 1 |
| Q3 2023 | $170K | 1 |
| Q4 2023 | $140K | 1 |
| Q1 2024 | $240K | 1 |
| Q2 2024 | $160K | 1 |
| Q3 2024 | $160K | 1 |
| Q4 2024 | $170K | 1 |
| Q1 2025 | $250K | 1 |
| Q2 2025 | $220K | 1 |
| Q3 2025 | $230K | 1 |
| Q4 2025 | $230K | 1 |
| Q1 2026 | $250K | 1 |
| Q2 2026 | $350K | 1 |
Policy issues the reports name
- Health issues14 reports
- Accounting1 reports
A report that names several issues counts once for each.
Who was lobbied
- HOUSE OF REPRESENTATIVES14 reports
- SENATE14 reports
- Executive Office of the President (EOP)6 reports
- Health & Human Services, Dept of (HHS)5 reports
- Centers For Medicare and Medicaid Services (CMS)1 reports
- Securities & Exchange Commission (SEC)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseBeone Medicines USA | $3.1M | 15 quarters |
Former officials lobbying for it
No lobbyist with a covered position.
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $350K |
| 04/20for Q1 | In-house | $250K |
| 01/20for Q4 2025 | In-house | $230K |
| 25/10/20for Q3 2025 | In-house | $230K |
| 25/07/21for Q2 2025 | In-house | $220K |
| 25/04/21for Q1 2025 | In-house | $250K |
| 25/01/24for Q4 2024 | In-house | $170K |
| 25/01/21for Q4 2024 | In-house | $180K |
| 24/10/20for Q3 2024 | In-house | $160K |
| 24/07/22for Q2 2024 | In-house | $160K |
| 24/04/22for Q1 2024 | In-house | $240K |
| 24/01/22for Q4 2023 | In-house | $140K |
| 23/10/20for Q3 2023 | In-house | $170K |
| 23/07/20for Q2 2023 | In-house | $140K |
| 23/04/21for Q1 2023 | In-house | $250K |
| 23/01/20for Q4 2022 | In-house | $120K |